TCTR20190423002尚未招募4 期
Pharmacokinetics of rifapentine and isoniazid and NAT2 and SLCO1B1 polymorphisms in pediatric Thai patients with latent tuberculosis infection
submitted proposal for HSRI funding of tuberculosis0 个研究点目标入组 25 人开始时间: 2019年4月23日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 2 Years 至 18 Years（—）
- 性别
- All
入选标准
- •-Male or female aged 2-18 years
- •-Newly diagnosed LTBI patientsÂ
- •-Informed consent
排除标准
- •-Body weight <10 kg
- •-Acute hepatitis
研究者
相似试验
招募中
不适用
'The effect of two treatment regimens: weekly rifapentine and isoniazid (3HP), compared to 4 months of daily rifampicin (4RIF) on adherence to treatment for latent tuberculosisACTRN12618001672246Royal Prince Alfred Hospital, Sydney Local Health District210
尚未招募
1 期
SOFIA StudyPharmacodynamics and pharmacokinetics of interferon formulations in healthy volunteers.RPCEC00000118Center for Genetic Engineering and Biotechnology (CIGB), in Havana.16
进行中（未招募）
不适用
Effects of rifampicin on the pharmacokinetics and pharmacodynamics of sublingual and intravenous buprenorphineEUCTR2012-002871-32-FITurku University hospital
Unknown
不适用
Isoniazid or Rifampicin and Isoniazid Preventive Therapy for children exposed to TB - the IRIPT trialTuberculosisPACTR201101000273931Christian Wejse880
已完成
不适用
Comparison of the pharmacokinetics between the initial and reduced dose of S-1 in the patients with locally advanced head and neck cancerlocally advanced head and neck cancerJPRN-UMIN000025205ational Cancer Center Hospital East25